Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Oct 6, 2018Diabetologia

Managing high blood sugar in type 2 diabetes: 2018 guidelines from major diabetes associations

AI simplified

GLP-1 TherapiesGLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

New recommendations emphasize lifestyle management and support for type 2 diabetes management.

  • A systematic review of literature since 2014 informed updates to diabetes management recommendations.
  • Weight loss strategies, including lifestyle changes, medication, and surgical interventions, are recommended for individuals with obesity.
  • For patients with cardiovascular disease, SGLT2 inhibitors or GLP-1 receptor agonists with proven cardiovascular benefits are advised.
  • SGLT2 inhibitors are recommended for patients with chronic kidney disease or clinical heart failure alongside atherosclerotic cardiovascular disease.
  • GLP-1 receptor agonists are generally recommended as the first injectable medication for diabetes management.

AI simplified

Full Text

Full text is available at the source.
View full text (HTML) ↗View full text (PDF) ↗

Related papers

Oct '18
Guidelines for Managing High Blood Sugar in Type 2 Diabetes, 2018
cited by 2,226 papers
research support, n.i.h., extramural
Dec '22
Use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes patients based on 2019 European and American treatment guidelines
top 5% journal
cited by 32 papers
research support, non-u.s. gov't
Dec '19
Updated 2019 Guidelines for Managing High Blood Sugar in Type 2 Diabetes from the American and European Diabetes Associations
top 1% journal
cited by 983 papers
historical article
Feb '25
GLP-1 receptor drugs for people with diabetes and long-term kidney disease
cited by 10 papers
systematic review
Mar '25
Improving prescriptions of two diabetes medicines for high-risk patients in Veterans Affairs clinics
top 20% journal
cited by 11 papers
journal article
May '25
Glucagon-like peptide-1 drugs vs. sodium/glucose transporter inhibitors for reducing kidney failure and death in type 2 diabetes patients with kidney disease
top 5% journal
cited by 6 papers
comparative study

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #35
Semaglutide linked to 2.5x higher risk of sudden vision loss
3 days ago7 studies
issue #34
Tirzepatide users had 18.4% weight loss vs 11.9% with semaglutide in head-to-head trial
1 week ago7 studies
issue #33
Semaglutide linked to 53% lower risk of death in dialysis patients with diabetes
2 weeks ago7 studies
issue #32
60% of weight lost on GLP-1 drugs returns within a year of stopping
3 weeks ago7 studies
issue #31
Semaglutide linked to 54% lower risk of new sleep apnea cases in 1.25 million patients
4 weeks ago7 studies
issue #30
Tirzepatide beats semaglutide for heart protection in 70,672 non-diabetic adults with obesity
5 weeks ago7 studies
issue #29
Stopping GLP-1 drugs before endoscopy cuts stomach content risk from 25% to 3%
6 weeks ago7 studies
issue #28
Semaglutide linked to 74-fold higher risk of vision-threatening eye condition
7 weeks ago3 studies
issue #27
GLP-1 drugs linked to 18% lower risk of substance use disorders in 524,817 veterans
8 weeks ago7 studies
issue #26
86.5% of patients on semaglutide or tirzepatide lost at least 5% of body weight at 6 months in Medicaid study
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief